Varicella Virus Vaccination in the United States

被引：17

作者：

Shaw, Jana ^{[1
]}

Gershon, Anne A. ^{[2
]}

机构：

[1] SUNY Upstate Med Univ, Dept Pediat, Syracuse, NY 13210 USA

[2] Columbia Univ Coll Phys & Surg, Dept Pediat, 630 W 168th St, New York, NY 10032 USA

来源：

VIRAL IMMUNOLOGY | 2018年 / 31卷 / 02期

关键词：

varicella zoster virus; varicella vaccine; latent virus; ZOSTER SUBUNIT VACCINE; HERPES-ZOSTER; MOLECULAR ANALYSIS; CLINICAL-TRIALS; ADVERSE EVENT; LONG-TERM; CHILDREN; EPIDEMIOLOGY; SAFETY; IMMUNIZATION;

D O I：

10.1089/vim.2017.0136

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Varicella zoster virus (VZV) is the cause of chickenpox (varicella) and shingles (zoster), and was once responsible for over 4 million infections in the United States annually. The development of a live attenuated VZV vaccine was initially viewed with extreme skepticism. Nonetheless, a VZV vaccine was developed in the 1970s by Takahashi and his colleagues in Japan and was eventually licensed in the US. It is now known to be one of the safest and most effective vaccines available and is administered worldwide. Here are described important factors that contributed to the successful research and licensure of the highly successful VZV vaccine.

引用

页码：96 / 103

页数：8

共 64 条

[11]

BRUNELL PA, 1975, LANCET, V1, P98

[12]

BRUNELL PA, 1978, PEDIATRICS, V62, P858

[13] PREVENTION OF VARICELLA BY ZOSTER IMMUNE GLOBULIN [J].

BRUNELL, PA ;

ROSS, A ;

MILLER, LH ;

KUO, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1969, 280 (22) :1191-&

[14]

Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P944

[15] Safety of varicella vaccine after licensure in the United States: Experience from reports to the vaccine adverse event reporting system, 1995-2005 [J].

Chaves, Sandra S. ;

Haber, Penina ;

Walton, Kimp ;

Wise, Robert P. ;

Izurieta, Hector S. ;

Schmid, D. Scott ;

Seward, Jane F. .

JOURNAL OF INFECTIOUS DISEASES, 2008, 197 :S170-S177

[16] Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster [J].

Chen, JJ ;

Zhu, ZL ;

Gershon, AA ;

Gershon, MD .

CELL, 2004, 119 (07) :915-926

[17] The Varicella-Zoster Virus Genome [J].

Cohen, Jeffrey I. .

VARICELLA-ZOSTER VIRUS, 2010, 342 :1-14

[18] Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older [J].

Cunningham, A. L. ;

Lal, H. ;

Kovac, M. ;

Chlibek, R. ;

Hwang, S. -J. ;

Diez-Domingo, J. ;

Godeaux, O. ;

Levin, M. J. ;

McElhaney, J. E. ;

Puig-Barbera, J. ;

Abeele, C. Vanden ;

Vesikari, T. ;

Watanabe, D. ;

Zahaf, T. ;

Ahonen, A. ;

Athan, E. ;

Barba-Gomez, J. F. ;

Campora, L. ;

de Looze, F. ;

Downey, H. J. ;

Ghesquiere, W. ;

Gorfinkel, I. ;

Korhonen, T. ;

Leung, E. ;

McNeil, S. A. ;

Oostvogels, L. ;

Rombo, L. ;

Smetana, J. ;

Weckx, L. ;

Yeo, W. ;

Heineman, T. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11) :1019-1032

[19] RECOMBINATION IN TISSUE-CULTURE BETWEEN VARICELLA-ZOSTER VIRUS-STRAINS [J].

DOHNER, DE ;

ADAMS, SG ;

GELB, LD .

JOURNAL OF MEDICAL VIROLOGY, 1988, 24 (03) :329-341

[20] CONSEQUENCES OF VARICELLA AND HERPES-ZOSTER IN PREGNANCY - PROSPECTIVE-STUDY OF 1739 CASES [J].

ENDERS, G ;

MILLER, E ;

CRADOCKWATSON, J ;

BOLLEY, I ;

RIDEHALGH, M .

LANCET, 1994, 343 (8912) :1548-1551

← 1 2 3 4 5 6 7 →